A5059745749- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Acute Lymphoblastic Leukemia research
- Liver Diseases and Immunity
- Diverticular Disease and Complications
- Gastric Cancer Management and Outcomes
- Chronic Lymphocytic Leukemia Research
- Pregnancy and Medication Impact
- Immunodeficiency and Autoimmune Disorders
- Celiac Disease Research and Management
- Autoimmune and Inflammatory Disorders
- Stoma care and complications
- Esophageal Cancer Research and Treatment
- Mycobacterium research and diagnosis
- Colorectal Cancer Screening and Detection
- Gastrointestinal Tumor Research and Treatment
- Helicobacter pylori-related gastroenterology studies
- Esophageal and GI Pathology
- Health Systems, Economic Evaluations, Quality of Life
- Folate and B Vitamins Research
- Pancreatic and Hepatic Oncology Research
- Diagnosis and treatment of tuberculosis
- Adolescent and Pediatric Healthcare
- Cytomegalovirus and herpesvirus research
Concord Repatriation General Hospital
2013-2025
Macquarie University
2016-2025
Western Sydney University
2016-2024
Blacktown & Mount Druitt Hospital
2016-2024
Sydney Local Health District
2016-2023
Camden and Campbelltown Hospitals
2022
The University of Sydney
2014-2021
Guy's and St Thomas' NHS Foundation Trust
2013-2017
St Thomas' Hospital
2013-2017
Migration Institute of Australia
2017
Summary Background Smoking demonstrates divergent effects in Crohn's disease ( CD ) and ulcerative colitis UC ). frequency is greater deleterious to its course. Conversely, primarily a of nonsmokers ex‐smokers, with reports amelioration active smoking. Aim To determine the prevalence smoking on progression surgery well‐characterised cohort inflammatory bowel diseases IBD patients. Methods Patients data Sydney Cohort were included. Demographic, phenotypic, medical, surgical hospitalisation...
Background The global COVID-19 pandemic has impacted on the mental health of individuals, particularly those with chronic illnesses. We aimed to quantify stress, anxiety and depression among individuals Inflammatory bowel disease (IBD) in Australia during pandemic. Methods An electronic survey was made available IBD patients Australia-wide from 17 June 12 July 2020. Respondents an underlying diagnosis over 18 years age were included. A validated questionnaire (Depression, Anxiety, Stress...
The impact of thiopurine de-escalation while on vedolizumab versus continuing therapy in ulcerative colitis (UC) is unclear. We aimed to determine the effect withdrawal for patients with UC remission vedolizumab.
Inflammatory bowel diseases (IBD) may result in disability. We aim to validate a novel scoring system for the IBD disability index (IBD-DI), and identify predictors of its correlation with work absenteeism. This prospective ambulatory clinic cohort study measured IBD-DI, Crohn's Disease Activity Index (CDAI) disease (CD) or partial Mayo score (pMayo) ulcerative colitis (UC), IBDQ quality-of-life, Work Productivity Impairment. Negative IBD-DI represented greater Validation tests were...
Earlier introduction of immunomodulators (IM) thiopurine or methotrexate is advocated to improve Crohn's disease (CD) outcomes, but whether abdominal surgery can be prevented remains controversial.A specialist-referred cohort CD was recruited from 1970 2009. Early IM use defined as commencement azathioprine within 3 years diagnosis and adherence at least 6 months. Propensity score matching conducted correct for confounders influencing early introduction. Outcomes interest were rates initial...
BackgroundCrohn's disease (CD) is a risk factor for vitamin B12 deficiency due to frequent involvement of the terminal ileum. Conventional screening with serum relatively insensitive and measures total concentration, which minority present in biologically active form. Holotranscobalamin (holoTC) combined methylmalonic acid (MMA) believed be more accurate identifying impaired status. We evaluated prevalence factors using holoTC supported by MMA among patients CD.
Background/Aims Medication non-adherence is common in inflammatory bowel diseases (IBD). The short-term consequences of include increased disease relapse but the long-term impact upon patients terms daily functional impairment are less well characterized. Identifying negative outcomes, such as disability, may encourage adherence. Methods Consecutive ambulatory IBD subjects completed Adherence Rating Scale (MARS; defined ≤16), Inflammatory Bowel Diseases Disability Index (IBD-DI; disability:...
Background Exclusive enteral nutrition (EEN) is a potentially effective but underused therapy for Crohn’s disease (CD) in adults. It first-line induction treatment paediatric patients remains second-line or third-line Objective To analyse the evidence EEN adult with CD, and summarise this narrative review. Methods In April/May 2020 July 2021, literature search was performed using Medical Subject Headings (MeSH) terms: ‘Crohn’s disease’, ‘CD’, ‘inflammatory bowel ‘IBD’, ‘exclusive nutrition’,...
<b>Background and study aims:</b> Complete Barrett's excision (CBE) of short-segment high grade dysplasia (HGD) early esophageal adenocarcinoma by stepwise endoscopic resection is a precise staging tool, detects covert synchronous disease, may produce sustained treatment response. Esophageal stricture the most commonly reported complication CBE although risk factors have not yet been clearly defined. <b>Patients methods:</b> Data were recorded prospectively on patients with limited...
Abstract Background Disease clearance (DC), defined as combined clinical, endoscopic and histologic remission, has been proposed the ultimate therapeutic target in ulcerative colitis (UC). However, addition of faecal calprotectin (FC) remission to DC, now ‘extensive disease (EDC)’, predicting for relapse is unknown. We aimed explore use composite endpoints, including DC EDC, long-term outcomes UC patients on vedolizumab (VED). Methods The phase IV Vedolizumab Immunomodulator Enforced...
Abstract Background Biochemical, endoscopic and histologic endpoints are commonly used to objectively define remission status in ulcerative colitis (UC). Little data exists on the correlation of these from prospectively collected samples based a well-defined protocol. Also, optimal faecal calprotectin (FC) values that predict histo-endoscopic lacking. Methods The phase IV Vedolizumab Immunomodulator Enforced Withdrawal Study (VIEWS) recruited 62 patients with UC vedolizumab steroid-free...
Most patients with Crohn's disease still require surgery despite significant advances in medical therapy, surveillance, and management strategies.The purpose of this study was to assess surgical strategies outcomes disease, including recurrence emergency surgery.This a multicenter, retrospective review prospectively collected database.A specialist-referred cohort between 1970 2009 studied.Included were 972 who referred the Sydney Inflammatory Bowel Disease database.Main interest rates major...
Thioguanine (TG) is efficacious in inflammatory bowel disease (IBD), but its toxicity, particularly nodular regenerative hyperplasia (NRH) of the liver, has limited use. We assessed long-term clinical outcomes and safety TG patients whom were intolerant or refractory to conventional immunomodulators.This a retrospective, single-centre study IBD treated with from 2001-2013. Response was defined as remission (Harvey-Bradshaw Index < 5 for Crohn's (CD), Simple Clinical Colitis Activity 4...
Background: Concomitant cytomegalovirus (CMV) is highly prevalent in acute severe ulcerative colitis (ASUC) but data for outcomes of CMV positivity ASUC and the benefit antiviral therapy remain unclear. Objectives: We aim to determine impact positivity, therapy, on such as colectomy-free survival, length hospital stay readmission rate, among hospitalized patients with ASUC. Design: This a retrospective, multicentre study admitted Methods: was diagnosed from blood DNA inpatient colonic...
Abstract Background & Aims Epidemiological data on primary sclerosing cholangitis ( PSC ) outside the Northern hemisphere are limited. Similarly, impact of inflammatory bowel disease IBD outcomes remains unclear. We aimed to study epidemiology and patients with without in an Australian cohort. Methods retrospectively studied attending two tertiary referral hospitals over 20 years. Diagnosis was made according international guidelines by positive cholangiography and/or liver biopsy (for...
The benefit of concomitant immunomodulation with adalimumab (ADA) in Crohn's disease is poorly understood. We aimed to compare ADA monotherapy combination therapy thiopurines, stratified by thioguanine nucleotides (TGNs). Retrospective observational study induction and maintenance. Thiopurines were classified according TGNs (>235 pmol/8 × 108 red blood cell therapeutic). At induction, response was more frequent than (83% versus 61%, P = 0.02) therapeutic compared subtherapeutic (87% 70%...
INTRODUCTION: Comparative effectiveness research provides data on the relative benefits and risks between treatments. In Crohn's disease (CD), however, there are few head-to-head studies comparing advanced therapies none with long-term follow-up. Real-world effectiveness, defined by treatment persistence, obtained from prospective population-based patient cohorts, may help determine best sequencing positioning of biological agents. METHODS: We analyzed prospectively collected Australian...
The use of immunomodulators (IMs) is often avoided in elderly patients with inflammatory bowel disease (IBD) due to concerns about complications. Our aim compare the IMs and younger Crohn's (CD) or ulcerative colitis (UC) identify markers that predict their use.In this retrospective cohort study, diagnosed IBD from 1970 2009 were recruited "Sydney Cohort." Patients at age 60 years old older between 16 40 classified as "elderly-onset" "young-onset" respectively.A total 255 elderly-onset (115...